Interview with the Computer-Aided Drug Design (CADD) Department
The computer-aided drug design talk about exciting developments awaiting us this year.
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.” An in depth interview with PinotBio
The computer-aided drug design talk about exciting developments awaiting us this year.
Carbohydrate chemistry at Symeres
Symeres has a proven track record in the synthesis of complex carbohydrates and related molecules.
An interview with Yadan Chen and Paul O’Shea
An interview with Yadan Chen and Paul Shea, the heads of Symeres’ daughter company Exemplify.
We’re expanding our laboratory facilities in Boston
We are expanding our chemistry capabilities near Boston, US.
Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities
Symeres announces the acquisition of Oncolines, a Dutch based CRO
Symeres CZ passed commercial inspection
Our team at Symeres CZ developed a new process for the production of the generic product Penfluridol.
Linkers and conjugation chemistry at Symeres
Symeres has considerable experience with a range of linkers and (bio)conjugates.
Chiral chemistry at Symeres
We apply all state-of-the-art-chiral technologies to obtain the desired compound in high enantiomeric purity.
